An observational study in Myopia, sponsored by Berkeley Eye Center. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Berkeley Eye Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.
Among the 342 studies in Myopia with a site in United States, this one is the 13th largest by enrollment of the 46 observational ones that give a count, is one of 31 that started in 2023, is one of 48 observational ones, and was the 287th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ages 40+
Ohio State University · Sites in United States
Ages 18–38
CooperVision International Limited (CVIL) · Sites in United States, Spain
Ages 7–35
Stanford University · Sites in United States
Ages 22–59
Jaeb Center for Health Research · Sites in United States
Ages 5–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 15 · Phase 4 22
First in 1995; this study’s year is marked. 31 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 150 across 204 observational studies indexed under Myopia.
Median enrollment 68 across the 294 interventional studies, 91 across the 46 observational. Of the 279 that completed or were terminated, 175 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
204 of 342 have an industry lead sponsor. The 10 most frequent:
Berkeley Eye Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Berkeley Eye Center has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
13 of the studies in Myopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07679048Rochester Institute of TechnologyMeasuring How Quickly the Eye Focuses After Sustained Viewing of Close-up Images and Videos | 2026-12-15 |
| NCT05893979SightGlass Vision, Inc.Myopia Control Spectacle Lens Cessation Study | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 342 studies in Myopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional prospective, comparative study of white-to-white, corneal thickness, and anterior chamber depth measurements as taken on the Orbscan II compared to the IOL Master 700 (Zeiss), IOL Master 500 (Zeiss), Atlas 9000 (Zeiss), Lenstar 900 (Haag-Streit), Argos (Alcon), iTrace (Tracey), Pentacam (Oculus), and manual calipers.
This is a non-interventional prospective, single center, bilateral, comparative study of white-to-white, corneal thickness, and anterior chamber depth measurements as taken on the Orbscan II compared to the IOL Master 700 (Zeiss), IOL Master 500 (Zeiss), Atlas 9000 (Zeiss), Lenstar 900 (Haag-Streit), Argos (Alcon), iTrace (Tracey), Pentacam (Oculus), and manual calipers. Additional biometric devices or external photography may be included as well.
Myopic patients with a spherical equivalent of at least -1.00D with healthy eyes and no prior eye surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Myopic patients with a diopter of at least -1.00
Diagnostic Test: Orbscan II · Diagnostic Test: IOL Master 700 · Diagnostic Test: IOL Master 500 · Diagnostic Test: Atlas 9000 · Diagnostic Test: Lenstar 900 · Diagnostic Test: Pentacam · Diagnostic Test: iTrace · Diagnostic Test: Argos · Diagnostic Test: Manual caliper measurement
Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Diagnostic assessment to measure white-to-white.
Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Diagnostic assessment to measure white-to-white and corneal thickness.
Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Manual diagnostic assessment to measure white-to-white.
The Correlation of White-to-white Measurements Between Biometric Devices.
The determination of the degree of correlation of white-to-white measurements between various biometric devices and the Orbscan II.
Time frame: Day of visit
The Correlation of Anterior Chamber Depth Measurements Between Biometric Devices.
The determination of the degree of correlation of anterior chamber depth measurements between various biometric devices and the Orbscan II.
Time frame: Day of visit
The Correlation of Corneal Thickness Measurements Between Biometric Devices.
The determination of the degree of correlation of corneal thickness measurements between various biometric devices and the Orbscan II.
Time frame: Day of visit
| Milestone | Myopic -1.00D |
|---|---|
| Started | 204 |
| Completed | 204 |
| Not completed | 0 |
The determination of the degree of correlation of white-to-white measurements between various biometric devices and the Orbscan II.
| Pearson correlation r | Argos | Atlas 9000 | Manual Caliper | IOLMaster 500 | IOLMaster 700 | iTrace | Lenstar LS900 | Pentacam AXL Wave | Pentacam HR |
|---|---|---|---|---|---|---|---|---|---|
| The Correlation of White-to-white Measurements Between Biometric Devices. | 0.89 (0.87 to 0.91) | 0.65 (0.59 to 0.71) | 0.53 (0.46 to 0.60) | 0.60 (0.54 to 0.66) | 0.82 (0.78 to 0.85) | 0.78 (0.74 to 0.82) | 0.87 (0.84 to 0.89) | 0.84 (0.81 to 0.87) | 0.84 (0.81 to 0.87) |
The determination of the degree of correlation of anterior chamber depth measurements between various biometric devices and the Orbscan II.
| Pearson correlation r | Argos | IOLMaster 500 | IOLMaster 700 | Lenstar LS900 | Pentacam AXL Wave | Pentacam HR |
|---|---|---|---|---|---|---|
| The Correlation of Anterior Chamber Depth Measurements Between Biometric Devices. | 0.91 (0.90 to 0.93) | 0.39 (0.31 to 0.47) | 0.33 (0.24 to 0.41) | 0.41 (0.33 to 0.49) | 0.95 (0.94 to 0.96) | 0.96 (0.96 to 0.97) |
The determination of the degree of correlation of corneal thickness measurements between various biometric devices and the Orbscan II.
| Pearson correlation r | Argos | IOLMaster 700 | Lenstar LS900 | Pentacam AXL Wave | Pentacam HR |
|---|---|---|---|---|---|
| The Correlation of Corneal Thickness Measurements Between Biometric Devices. | 0.82 (0.78 to 0.85) | 0.80 (0.76 to 0.83) | 0.68 (0.63 to 0.73) | 0.68 (0.62 to 0.73) | 0.73 (0.68 to 0.77) |
Collected over Day of visit. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Argos | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| Atlas 9000 | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| Manual Caliper | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| IOLMaster 500 | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| IOLMaster 700 | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| iTrace | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| Lenstar LS900 | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| Pentacam AXL Wave | 0/161 (0%) | 0/161 (0%) | 0/161 (0%) |
| Pentacam HR | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| Orbscan II | 0/204 (0%) | 0/204 (0%) | 0/204 (0%) |
| Age, Categorical(Participants) | Myopic -1.00D |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 204 |
| >=65 years | 0 |
| Sex/Gender, Customized(Participants) | Myopic -1.00D |
|---|---|
| Not disclosed | 204 |
| Race and Ethnicity Not Collected(Participants) | Myopic -1.00D |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Feb 2024, 6 months.
Results were first posted in May 2025, 1 year 2 months after primary completion.
Of 87 non-industry observational studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's 6 months is below that.
Counting every sponsor, half of 96 studies reached it within 24 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Berkeley Eye Center